Kapat
Popüler Videolar
Moods
Türler
English
Türkçe
Popüler Videolar
Moods
Türler
Turkish
English
Türkçe
Dr. Perl on Challenges of Implementing Immunotherapy in AML
1:10
|
Loading...
Download
Lütfen bekleyiniz...
Type
Size
İlgili Videolar
Dr. Perl on Challenges of Implementing Immunotherapy in AML
1:10
|
Challenges with immunotherapy in AML: target antigen selection, T-cell exhaustion and more
2:15
|
Dr. Perl on Choosing the Optimal Therapy in AML
1:27
|
Key challenges in immunotherapy for AML
1:12
|
Dr. Perl on Evolving Treatment in AML
1:44
|
Challenges to Overcome With CAR T-Cell Therapy for Acute Myeloid Leukemia
1:29
|
The role of immunotherapy in the AML treatment landscape
3:47
|
What is immunotherapy for AML?
3:04
|
Dr. Perl on Remaining Challenges with CAR T-Cell Therapy
1:31
|
Using Antibody-Drug Conjugates for Treatment of AML
0:58
|
Current concepts and future developments in T-cell-based immunotherapy of AML
5:40
|
Challenges in CAR-T therapy for myeloid malignancies
1:27
|
Immuno-oncology: what is next for AML?
1:26
|
Finding the right targets for CAR T-cell therapy in AML
3:07
|
Defining the Challenges of FLT3 Inhibition in AML
4:13
|
Oncotarget: Nanoparticles Target Acute Myeloid Leukemia
0:53
|
Challenges in treating patients with TP53-mutated AML and future outlooks
1:53
|
What’s new in immunotherapy for AML?
5:15
|
Dr. Roboz on Challenges With CAR T-cell Therapy in ALL
1:33
|
The clinical meaning of MRD below the threshold of mCR in AML
0:44
|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa
